stockportfolio.pro
Emergent BioSolutions Inc. (EBS)
Healthcare · Drug Manufacturers - Specialty & Generic · NYSE
Emergent BioSolutions Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $488.80M | $560.90M | $782.40M | $1.11B | $1.58B | $1.77B | $1.08B | $1.02B | $1.01B | $705.20M |
| Gross profit | $362.50M | $373.20M | $460.10M | $672.50M | $925.20M | $891.30M | $383.00M | $317.60M | $332.30M | $379.00M |
| Net income | $51.80M | $82.60M | $62.70M | $54.50M | $305.80M | $219.50M | $-211.60M | $-760.50M | $-190.60M | $52.60M |
| Net margin | 10.6% | 14.7% | 8.0% | 4.9% | 19.4% | 12.4% | -19.7% | -74.3% | -18.8% | 7.5% |
Source: Emergent BioSolutions Inc. SEC filings (10-K). 17 years of history available in the interactive view.
What growth is priced into EBS stock?
At today's market cap of $427.73M, Emergent BioSolutions Inc. is priced for free-cash-flow growth of about -22.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $156.80M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -16.9%/yr over the last five fiscal years and revenue -14.9%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 17 years of Emergent BioSolutions Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track EBS in your portfolio →
Emergent BioSolutions Inc. financial history by metric
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Emergent BioSolutions Inc. — frequently asked questions
What is Emergent BioSolutions Inc.'s revenue?
Emergent BioSolutions Inc. (EBS) reported revenue of $705.20M for fiscal year 2025, down 30.4% from the prior year, according to its SEC filings.
Is Emergent BioSolutions Inc. profitable?
Yes. EBS earned net income of $52.60M in fiscal 2025, a net margin of 7.5%.
What is EBS's P/E ratio?
Emergent BioSolutions Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Emergent BioSolutions Inc. growing?
EBS's revenue grew at roughly -14.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Emergent BioSolutions Inc. have?
As of fiscal year 2025, EBS carried roughly $572.10M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Emergent BioSolutions Inc.'s gross margin?
EBS's gross margin was 53.7% in fiscal 2025 — gross profit of $379.00M on revenue of $705.20M.
What is Emergent BioSolutions Inc.'s market cap?
Emergent BioSolutions Inc. (EBS) has a market capitalization of about $427.73M, based on the latest data in our nightly-refreshed cache.
When does Emergent BioSolutions Inc.'s fiscal year end?
EBS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into EBS stock?
At today's market cap of $427.73M, Emergent BioSolutions Inc. is priced for free-cash-flow growth of about -22.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $156.80M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -16.9%/yr over the last five fiscal years and revenue -14.9%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Emergent BioSolutions Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.